Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

885
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
885
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

Related Experiment Video

Updated: Dec 20, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Bimatoprost Implant: First Approval.

Matt Shirley1

  • 1Springer Nature, Private Bag 65,901, Mairangi Bay, Auckland, 0754, New Zealand. dra@adis.com.

Drugs & Aging
|May 25, 2020
PubMed
Summary
This summary is machine-generated.

Bimatoprost implant offers sustained drug delivery to lower eye pressure for glaucoma patients. This new treatment option provides a 4-6 month duration for reducing intraocular pressure (IOP).

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.0K

Related Experiment Videos

Last Updated: Dec 20, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.0K

Area of Science:

  • Ophthalmology
  • Drug Delivery Systems
  • Glaucoma Research

Background:

  • Open-angle glaucoma (OAG) and ocular hypertension (OHT) are common conditions characterized by elevated intraocular pressure (IOP).
  • Current treatments often involve frequent topical eye drops, posing challenges for patient adherence and consistent IOP management.
  • Sustained-release drug delivery systems offer a potential alternative for improved IOP control.

Purpose of the Study:

  • To summarize the development milestones of the bimatoprost implant (Durysta™).
  • To highlight the regulatory approval process for this novel sustained-release formulation.
  • To provide an overview of bimatoprost implant's application in managing intraocular pressure.

Main Methods:

  • Development of a biodegradable, solid polymer drug delivery system for sustained bimatoprost release.
  • Intracameral administration of the bimatoprost implant.
  • Clinical trials evaluating the efficacy and safety of the bimatoprost implant for IOP reduction.

Main Results:

  • The bimatoprost implant demonstrated sustained release of bimatoprost, lowering IOP over a 4- to 6-month period.
  • Received US FDA approval in March 2020 for reducing IOP in patients with OAG or OHT.
  • Clinical development program is ongoing to further evaluate its potential.

Conclusions:

  • The bimatoprost implant represents a significant advancement in sustained drug delivery for glaucoma management.
  • It offers a novel intracameral treatment option for patients with open-angle glaucoma and ocular hypertension.
  • The development milestones underscore the progression towards innovative solutions for chronic ocular conditions.